{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Possible HYs Law, >3x ULN ALT, >=2x ULN BIL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Possible HYs Law, >3x ULN ALT, >1.5x ULN INR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}],"title":"Hepato-cellular injury"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Bilirubin elevations, >=2x ULN BIL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Bilirubin elevations, >=2x ULN BIL and <2x ULN BIL"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"title":"ALT or AST elevations, >3x ULN ALT or AST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"ALT or AST elevations, >5x ULN ALT or AST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"ALT or AST elevations, >8x ULN ALT or AST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"ALT or AST elevations, >20x ULN ALT or AST"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"title":"ALT elevations, >3x ULN ALT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"ALT elevations, >5x ULN ALT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}],"title":"ALT elevations, >8x ULN ALT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"ALT elevations, >20x ULN ALT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"}]}],"title":"ALT elevations, >3x ULN ALT, <=3x ULN ALT Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}]}],"title":"ALP elevations, >=3x ULN ALP"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"title":"ALP elevations, >=3x ULN ALP and <3x ULN ALP"}],"denoms":[{"counts":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"83"}],"units":"Participants"}],"description":"Blood samples were collected for the assessment of hepatobiliary parameters. ALT=alanine aminotranserase; AST=aspartate aminotransferase; ALP=alkaline phosphatase; BIL=total bilirubin; INR=international normalized ratio; ULN=upper limit of normal. Hepato-cellular injury is defined as (ALT/ULN)/(ALP/ULN) \\>=5.","groups":[{"description":"Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG000","title":"GSK2118436 150 mg: No Prior Local Therapy"},{"description":"Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.","id":"OG001","title":"GSK2118436 150 mg: Prior Local Therapy"}],"paramType":"NUMBER","populationDescription":"ATS Population","reportingStatus":"POSTED","timeFrame":"From Screening until the conclusion of the study (up to 103 weeks)","title":"Number of Participants With the Indicated Hepatobiliary Laboratory Abnormalities","type":"SECONDARY","unitOfMeasure":"participants"}